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Best current estimates of neuropathic pain prevalence come from studies using screening tools detecting
pain with probable neuropathic features; the proportion experiencing signiﬁcant, long-term neuropathic
pain, and the proportion not responding to standard treatment are unknown. These ‘‘refractory’’ cases are
the most clinically important to detect, being the most severe, requiring specialist treatment. The aim of
this study was to estimate the proportion of neuropathic pain in the population that is ‘‘refractory,’’ and
to quantify associated clinical and demographic features. We posted self-administered questionnaires to
10,000 adult patients randomly selected from 10 general practitioner practices in 5 UK locations. The
questionnaire contained chronic pain identiﬁcation and severity questions, cause of pain, SF-12, EQ-
5D, S-LANSS (Self-administered Leeds Assessment of Neuropathic Signs and Symptoms), PSEQ (Pain
Self-Efﬁcacy Questionnaire), use of neuropathic pain medications, and health care utilisation. These data
were combined to determine the presence and characteristics of ‘‘refractory’’ neuropathic pain according
to the deﬁning features identiﬁed by a Delphi survey of international experts. Graded categories of
chronic pain with and without neuropathic characteristics were generated, incorporating the refractory
criteria. Completed questionnaires were returned by 4451 individuals (response rate 47%); 399 had
‘‘chronic pain with neuropathic characteristics’’ (S-LANSS positive, 8.9% of the study sample); 215
(53.9%) also reported a positive relevant history (‘‘Possible neuropathic pain’’); and 98 (4.5% of all Chronic
Pain) also reported an ‘‘adequate’’ trial of at least one neuropathic pain drug (‘‘Treated possible neuro-
pathic pain’’). The most refractory cases were associated with dramatically poorer physical and mental
health, lower pain self-efﬁcacy, higher pain intensity and pain-related disability, and greater health care
service use.
 2013 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY license. 1. Introduction
Neuropathic pain was recently re-deﬁned by the International
Association for the Study of Pain (IASP) and graded as ‘‘possible,’’
‘‘probable,’’ or ‘‘deﬁnite,’’ depending on the extent and results of
neurological assessment [23,48]. Best current estimates of the pop-
ulation prevalence of neuropathic pain come from studies using
validated screening tools that detect pain with possible neuro-
pathic features [6,46]. Chronic pain with neuropathic features
has been shown to affect around 7–8% of the general population.
The proportion of these meeting the IASP classiﬁcation of ‘‘possi-tudy of Pain. Published by Elsevie
Dundee, Medical Research
enzie Building, Kirsty Semple
nce).ble’’ neuropathic pain, therefore requiring consideration of speciﬁc
treatment or further assessment, is unknown. Similarly, the pro-
portion experiencing signiﬁcant, long-term neuropathic pain, not
responding to standard treatment, is unknown, though this is per-
haps the most clinically important and challenging subgroup.
The term ‘‘refractory neuropathic pain’’ has emerged in recent
literature [34,43,45], and deﬁnitions and descriptions vary mark-
edly. In a review of the epidemiology of refractory neuropathic
pain, Taylor (2006) included speciﬁc neuropathic pain conditions
and pain that was ‘‘persistent’’ [45]. The Scottish Medicines Con-
sortium describes patients with refractory neuropathic pain, as
those who ‘‘have not achieved adequate pain relief from, or have
not tolerated, conventional ﬁrst and second line treatments [35].’’
A more detailed deﬁnition was developed for use in a randomised
controlled trial of a new drug regimen [43] and includes speciﬁcr B.V. Open access under CC BY license. 
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least 6 months, pain severity score of at least 40 mm on a 0–
100 mm visual analogue scale, and nonresponse to usual care,
including treatment with gabapentin, a tricyclic antidepressant,
and a third potentially effective medication. Hansson et al.
(2009) proposed a deﬁnition of ‘‘pharmacoresistant neuropathic
pain’’ that would incorporate resistance to proven efﬁcacious
drugs, of appropriate duration, and with adequate dosage [20].
The authors concede that data are lacking to support an evi-
dence-based approach to the deﬁnition of these terms and call
for more studies and debate.
With refractory neuropathic pain deﬁned and classiﬁed in a
clinically and epidemiologically relevant way, it will be possible
to identify those people in the community who experience this
most severe neuropathic pain and who are in greatest need of spe-
cialist treatment. This will in turn allow an assessment of the scale
of the problem, identiﬁcation of risk factors for ‘‘refractoriness’’
(including those that are potentially modiﬁable), and the subse-
quent efﬁcient targeting of management or prevention strategies.
The apparent lack of such an agreed case deﬁnition for refractory
neuropathic pain and a means of case ascertainment have hindered
this endeavour. Recent research, however, involving an interna-
tional Delphi survey of experts, deﬁned ‘‘refractoriness’’ of neuro-
pathic pain for epidemiological research [42], with the following
key criteria: 1) there should have been a trial of treatment with
at least 4 drugs of known effectiveness in neuropathic pain; 2) each
of these drugs should have been tried for at least 3 months or until
adverse effects prevent adequate dosage or continued treatment;
3) despite this treatment, the intensity of pain should not have
been reduced by more than 30%, or should remain at a level of at
least 5 on a 0–10 scale; and/or it should continue to contribute sig-
niﬁcantly to poor quality of life.
We have previously described the prevalence, distribution, and
associated health of pain with neuropathic features in the general
population, compared with those without chronic (neuropathic)
pain [41,46]. The main aim of this study was to estimate the pro-
portion of neuropathic pain in the population that is ‘‘refractory,’’
and to quantify associated clinical and demographic features. In a
population-based study it is not practical to undertake detailed
neurological assessment on a sufﬁcient scale to identify ‘‘probable’’
or ‘‘deﬁnite’’ neuropathic pain, therefore we used the validated
Self-administered Leeds Assessment of Neuropathic Signs and
Symptoms (S-LANSS) questionnaire [4], supplemented by ques-
tions on diagnosis, to identify ‘‘possible’’ neuropathic pain. ‘‘Refrac-
toriness’’ was determined according to the above criteria. We
anticipated that the number of cases fully meeting all of these cri-
teria, and therefore being ascertained as truly ‘‘refractory,’’ would
be small. We therefore further aimed to measure the impact of
each criterion (apparent resistance to treatment, pain intensity,
pain-related quality of life) on overall prevalence and health out-
comes. To do this, we developed a graded categorisation, with
increasing ‘‘refractoriness’’ of neuropathic pain.2. Methods
2.1. Sample selection
In the UK, around 96% of the population is registered with a
general practitioner (family doctor, GP) [30]; a GP practice popula-
tion therefore approximately equates a general population sample.
This study surveyed a total of 10,000 individuals in 5 UK locations,
with 2 GP practices in each locality, each generating a random
sample of 1000 registered adult patients. In England, in Leeds, Lan-
caster, and Stafford, the National Institute for Health Research Clin-
ical Research Network [29] provided support in identifying andrecruiting practices and their patients. In Scotland, practices in
Grampian and Glasgow participated, supported by the Scottish Pri-
mary Care Research Network [37]. Each practice’s electronic regis-
ter was used to generate a random sample of patients aged over
18 years and the sample list was then screened by the GPs in each
practice, to exclude patients in whom inquiry might be insensitive
or inappropriate (for example, those with terminal illness or with
severe learning difﬁculties). Each excluded patient was replaced
by another, sampled randomly from the same practice register.
The study was conducted between November 2010 and March
2011. One reminder letter and an additional copy of the question-
naire were posted to nonrespondents approximately 3 weeks after
the ﬁrst questionnaire.
The questionnaire was developed to categorise ‘‘refractory neu-
ropathic pain’’ according to the expert deﬁnition generated by the
Delphi study [42]. It included: 1) chronic pain identiﬁcation ques-
tions and a measure of chronic pain with neuropathic characteris-
tics (S-LANSS); 2) a relevant patient history; 3) questions on the
number and duration of neuropathic pain medications tried; 4)
pain intensity (using the Chronic Pain Grade [CPG]), and 5)
health-related quality of life (SF-12 and EQ-5D). In order to further
explore the impact of these levels of refractoriness, we also col-
lected data on pain-related disability, pain self-efﬁcacy, and health
care utilisation.
2.2. Patient questionnaire
Questions were included on age, gender, smoking, marital and
employment status, educational attainment, and home ownership
(as a proxy for social class) [44]. These were similar to questions
used in previous studies of chronic (neuropathic) pain in the com-
munity [14,46].
2.2.1. Pain ascertainment/characteristics
Individuals with chronic pain were identiﬁed by afﬁrmative an-
swers to 2 questions: 1) Are you currently troubled by pain or dis-
comfort, either all the time or on and off? 2) Have you had this pain
or discomfort for more than 3 months? [21]. Identical case identi-
ﬁcation questions have been used in previous population-based re-
search on chronic pain [13,14,46]. Participants who responded
positively to both these questions were asked to indicate the site(s)
of their chronic pain and the most troublesome site by selecting
from a list that included: back; neck or shoulder; head, face or
teeth; stomach or abdomen; arms or hands; chest; hips; and legs
or feet [51]. Subsequent questions about pain, including the S-
LANSS questions, related to the single most troublesome site of
pain. The S-LANSS was used to identify pain with neuropathic
characteristics (NC) [4]; a 7-item questionnaire, it includes 5 ques-
tions about pain characteristics and 2 self-examination items, with
responses weighted to provide a maximum score of 24. A score of
12 or more has been found to have a positive predictive value for
neuropathic pain of 76% (95% conﬁdence interval [CI] 66.8–
84.2%) when compared with classiﬁcation by a pain specialist. Its
validity and reliability in identifying pain with NC with this cut-
off score in postal research has also been conﬁrmed [4]. Individuals
in this study who had an S-LANSS scoreP12 were therefore iden-
tiﬁed as cases and described as having ‘‘Chronic pain with NC.’’
Respondents were also asked to indicate whether any of the fol-
lowing common causes of pain had been diagnosed as the cause of
the chronic pain they had identiﬁed in the screening questions:
any type of neuralgia; back problems (such as slipped disc, back
surgery or sciatica); diabetes; cancer or cancer treatment/chemo-
therapy; human immunodeﬁciency virus; muscle problems e.g.
spasm, strains, tension; amputation of a limb; a surgical operation;
arthritis; shingles; multiple sclerosis; stroke; an accident that
damaged a nerve; or none of these. Responses to this question
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neuropathic pain’’ (i.e. muscle problems or arthritis) and ‘‘Possible
neuropathic pain’’ (other possible neuropathic pain causes listed),
and therefore, to indicate whether or not respondents had a ‘‘rele-
vant history.’’
The CPG, a 7-item instrument, was used to assess pain severity
based on its intensity and pain-related disability [52]. The CPG
questionnaire inquires about current, worst, and average pain in
the previous 3 months and classiﬁes its severity into 4 hierarchical
grades: Grade I (low disability-low intensity), Grade II (low disabil-
ity-high intensity), Grade III (high disability-moderately limiting),
and Grade IV (high disability-severely limiting). The CPG is valid
and reliable for use as a self-completion postal questionnaire in
the UK general population [39]. Only those who responded posi-
tively to the case-screening questions, which identiﬁed whether
chronic pain was present, were asked to complete the CPG
questionnaire.
2.2.2. Pain medication and health care use
Respondents were asked to indicate whether any neuropathic
pain medications had been prescribed either currently or in the
past. The list of pain medications was derived from recently pub-
lished and rigorously evidence-based guidelines on the pharmaco-
logical management of neuropathic pain [1,16,31] and the British
National Formulary [8]. These drugs were amitriptyline, carbamaz-
epine, duloxetine, gabapentin, lidocaine patch, morphine, nortrip-
tyline, oxcarbazepine, oxycodone, pregabalin, tramadol, and
venlafaxine. Respondents were asked to indicate whether they
were currently taking these medications and/or had taken them
in the past, to specify how long they had taken each one, and the
reasons they stopped taking them, for example, because of side ef-
fects or lack of effect. If they had taken the neuropathic pain drug
for at least 3 months, this was considered an ‘‘adequate trial,’’ as
was cessation because of side effects. In respondents who indicated
that they had taken any neuropathic pain medication but for
<3 months, or who selected ‘‘did not work’’ as the reason for cessa-
tion without an indication of the duration of treatment, this was
not considered an ‘‘adequate’’ trial.
Respondents were also asked to indicate the number of consul-
tations they had attended with a GP about their pain condition in
the previous 6 months, if they had ever attended a pain manage-
ment specialist/pain clinic, and to indicate which other health care
professionals they had consulted for their chronic pain.
2.2.3. Health-related quality of life
Assessment of health-related quality of life (HRQoL) in all
respondents was based on the Medical Outcomes Short-Form 12
scale (SF-12), a validated self-administered tool for measuring
health status derived from the SF-36 [53]. The SF-12 has been used
in large general population questionnaire studies of chronic pain
[2,9,26] and in speciﬁc neuropathic pain conditions, such asTable 1
Graded categories of chronic pain for analysis.
‘Chronic pain’. Afﬁrmative responses to the two chronic pain screening questions, (i) ar
(ii) Have you had this pain or discomfort for more than three months? [20]
 ‘Chronic pain without neuropathic characteristics’. Chronic pain (as above) an
 ‘Chronic pain with neuropathic characteristics’. Chronic pain and S-LANSS pos
 ‘Possible neuropathic pain’. Chronic pain; S-LANSS positive; and reported his
 ‘Untreated possible neuropathic pain’. Chronic pain, S-LANSS positive; reporte
ropathic pain medications
 ‘Treated possible neuropathic pain’. Chronic pain, S-LANSS positive; reported
least one neuropathic pain medication
 ‘Refractory possible neuropathic pain’. Chronic pain; S-LANSS positive; and re
of four or more drugs; and poor QoL OR pain severity greater than 5/10; an
S-LANSS, Self-administered Leeds Assessment of Neuropathic Signs and Symptoms.zoster-related pain [5]. SF-12 scores can be calculated in 8 health
domains: physical functioning, role physical, bodily pain, general
health, vitality, social functioning, role emotional, and mental
health. The scores are summarised into 2 component scores – men-
tal health (MCS) and physical health (PCS), with scores ranging
from 0 (worst possible health state) to 100 (best possible health
state). The participants’ scores on the SF-12-MCS and SF-12-PCS
were further categorised into tertiles: lowest third = ‘‘poor’’ HRQoL,
middle third = ‘‘moderate’’ HRQoL, and highest third = ‘‘good’’
HRQoL. A similar approach has been used by Nicholl et al. (2009)
[33].
The EQ-5D is a generic measure of health status and deﬁnes
health in terms of 5 dimensions: mobility, self-care, usual activities
(work, study, housework, family, or leisure), pain or discomfort,
and anxiety or depression, and is well validated in population stud-
ies [15,24]. A preference-based set of weights (or algorithm) is
used to calculate a single EQ-5D index-based utility score of
HRQoL, anchored by 1 (full health) and 0 (equal to death), with
some states being worse than death (<0) [22]. In addition, the
EQ-5D also includes a numerical rating scale ranging from 0 (worst
imaginable health state) to 100 (best imaginable health state), on
which respondents can rate their current health.
2.2.4. Pain self-efﬁcacy questionnaire
The Pain Self-Efﬁcacy Questionnaire (PSEQ) measures pain cog-
nition and self-conﬁdence in performing functional and social
activities, despite the presence of pain [32]. It has high intra-rater
reliability, internal consistency, and stability on retest. The PSEQ
includes 10 items, each with a 7-point scale, where 0 equals ‘‘not
at all conﬁdent’’ and 6 equals ‘‘completely conﬁdent,’’ and a total
score is calculated by summing the scores for each of the 10 items,
yielding a maximum possible score of 60, with higher scores
reﬂecting stronger self-efﬁcacy beliefs. There is good evidence that
higher self-efﬁcacy about managing pain is associated with more
positive treatment outcomes, higher return to work rates, better
adherence, more effective control of pain and effect, and better
prognosis [28].
2.3. Data analysis
Data were analysed using PASW Statistics for Windows (version
18.0; SPSS Inc, Chicago, IL, USA). Simple descriptive statistics and
cross-tabulations were used to estimate the prevalence of Chronic
pain with NC (i.e., S-LANSS score of 12 or more), ‘‘Possible neuro-
pathic pain’’ (S-LANSS score P12 and a relevant diagnosis from
the above list), and ‘‘Refractory’’ neuropathic pain (‘‘possible’’ cases
fulﬁlling the above criteria for refractoriness) [42]. Given the strin-
gency of the criteria for refractoriness, we also explored degrees of
‘‘refractoriness,’’ including those with an adequate trial of 0, 1, and
2 or more neuropathic pain medications, and different combina-
tions of pain severity and HRQoL. In addition, to explore thee you currently troubled by pain or discomfort, either all the time or on and off?
d S-LANSS score of <12
itive (S-LANSS questionnaire score P12)
tory of possible cause of neuropathic pain
d history of possible cause of neuropathic pain; and no reported history of neu-
history of possible cause of neuropathic pain; and reported adequate trial of at
ported history of possible cause of neuropathic pain; and reported adequate trial
d pain duration more than six months [41]
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plored sub-groups of those with ‘‘severe’’ pain (average pain inten-
sity P7/10) in those with and without NC.
For the purposes of analysis and comparison, graded categories
of chronic pain were identiﬁed (Table 1): ‘‘Chronic pain,’’ ‘‘Chronic
pain without NC,’’ ‘‘Chronic pain with NC,’’ ‘‘Possible neuropathic
pain,’’ ‘‘Untreated possible neuropathic pain,’’ ‘‘Treated possible
neuropathic pain,’’ and ‘‘Refractory possible neuropathic pain.’’
‘‘Chronic pain with and without NC’’ are mutually exclusive groups,
as are ‘‘Untreated possible neuropathic pain’’ and ‘‘Treated neuro-
pathic pain.’’ For all other chronic pain groups, individuals could be
in more than one due to the reported pain characteristics deemed
important for identifying neuropathic pain and ‘‘Refractory possi-
ble neuropathic pain’’ by international experts [42].
Chi-squared tests were used to test for associations and statis-
tical signiﬁcance between categorical sociodemographic variables,
and t-tests were used to explore the mean difference in normally
distributed continuous variables. All reported P values were from
2-sided tests, and a P value < 0.05 was used to denote statistical
signiﬁcance.
2.4. Ethical approval
The study was approved by North of Scotland Research Ethics
Committee, REC reference number 09/S0802/103.
3. Results
A total of 10,000 questionnaires were mailed by the Primary
Care Research Networks on the authors’ behalf. Of these, 347 were
returned as undelivered or unable to be completed due to illness or
learning disability. A total of 4541 completed questionnaires wereTable 2
Sociodemographic characteristics of respondents with No chronic pain and (Severe) Chron
No chronic pain
(n = 2296)
Chronic pain with
NC (n = 399)
Chronic pain
NC (n = 1611
Age, n (%)
18–39 years 654 (28.5) 60 (15.3) 234 (14.7)
40–59 years 928 (40.4) 167 (42.5) 622 (39.0)
60+ years 692 (30.1) 166 (42.2) 740 (46.4)
Gender
Men 1016 (44.3) 146 (36.8) 684 (42.5)
Women 1280 (55.7) 251 (63.2) 925 (57.5)
Marital status
Never married 382 (16.6) 55 (14.0) 166 (10.4)
Living as married 1614 (70.3) 245 (62.2) 1194 (74.5)
No longer married 290 (12.6) 94 (23.9) 243 (15.2)
Housing tenure
Owned/mortgaged 1914 (85.4) 261 (66.4) 1321 (82.6)
Council rent 190 (8.5) 92 (23.4) 188 (11.8)
Private rent/other 178 (7.8) 40 (10.2) 91 (5.7)
Employment
Employed 1483 (64.6) 151 (38.4) 774 (48.3)
Retired 562 (24.5) 137 (34.9) 638 (39.9)
Unable to work 28 (1.2) 77 (19.6) 70 (4.4)
Not employed/other 212 (9.2) 28 (7.1) 119 (7.4)
Education
No qualiﬁcations 323 (14.1) 115 (29.6) 345 (21.7)
Secondary school/equivalent 933 (40.6) 165 (42.5) 599 (37.7)
Higher education 1010 (44.0) 108 (27.8) 644 (40.6)
Smoking
Smoker 372 (16.2) 105 (26.4) 264 (16.4)
Ex-smoker 632 (27.5) 109 (27.5) 580 (36.1)
Never smoked 1288 (56.1) 183 (46.1) 761 (47.3)
a Chi-squared test; comparisons between ‘‘Chronic pain with NC’’ vs ‘‘Chronic pain wi
b Severe pain = average pain intensity score P7/10.returned, giving an overall corrected response rate of 47%. Re-
sponse rates varied between practices and ranged from 35% to
58%. The response rate also varied with age and gender, with non-
responders younger than responders (mean [SD] age, 44.5 [17.4]
years vs 53.4 [16.9] years, P < 0.001) and women more likely to re-
spond than men across all practices (57.5% vs 42.6%; P < 0.001).
These patterns were similar in each practice (data available on
request).
Of the 4541 returned questionnaires, 4498 individuals com-
pleted both of the screening questions for chronic pain status (43
individuals did not complete the 2 case-identiﬁcation questions
for chronic pain and were excluded from further analysis). Chronic
pain was reported by 2202 (48.5%; 95% CI 47.0–49.9%). S-LANSS
questionnaires were incomplete in 192 of these individuals. There-
fore, the study sample for analysis included 4306 individuals with
complete data: 2296 respondents with no chronic pain and 2010
respondents with any chronic pain; which comprised 1611 individ-
uals with Chronic pain without NC, and 399 with Chronic pain with
NC (S-LANSS positive). The 399 respondents who reported Chronic
pain with NC represented 8.9% (399/4451) of the study sample,
and 18.1% (399/2202) of those reporting any chronic pain Fig. 1.
3.1. Characteristics and severity of pain with neuropathic
characteristics and associated quality of life and pain self-efﬁcacy
There were signiﬁcant differences in all of the measured soci-
odemographic characteristics between respondents reporting
Chronic pain with NC and those reporting Chronic pain without
NC (Table 2) except for age (mean [SD] 56.0 [15.4] years vs 56.3
[15.3] years, P = 0.673). Individuals with Chronic pain with NC
were more likely to be women, no longer married, and living in
council-rented accommodation than individuals whose chronicic pain with and without neuropathic characteristics (NC), n (%).
without
)
P valuea Severe chronic pain
with NCb (n = 218)
Severe chronic pain
without NCb (n = 487)
P valuea
0.326 30 (14.0) 67 (13.9) 0.112
97 (45.3) 180 (37.4)
87 (40.7) 234 (48.7)
0.043 68 (31.3) 186 (38.3) 0.092
149 (67.7) 300 (61.7)
<0.001 31 (14.4) 50 (10.3) 0.005
127 (59.1) 348 (71.6)
57 (26.5) 88 (18.1)
<0.001 128 (59.8) 365 (75.4) <0.001
66 (30.8) 96 (19.8)
20 (9.3) 23 (4.8)
<0.001 67 (31.3) 191 (39.6) <0.001
75 (35.0) 204 (42.3)
57 (26.6) 45 (9.3)
15 (7.0) 42 (8.7)
<0.001 72 (34.1) 159 (33.1) 0.179
92 (43.6) 183 (38.1)
47 (22.3) 138 (28.7)
<0.001 66 (30.4) 107 (22.0) 0.003
49 (22.6) 168 (34.6)
102 (47.0) 211 (43.4)
thout NC’’ and ‘‘Severe chronic pain with NC’’ vs ‘‘Severe chronic pain without NC.’’
Table 3
Clinical and associated features associated with No Chronic pain and (Severe) chronic pain, with and without neuropathic characteristics (NC).
No chronic pain
(n = 2296)
Chronic pain with
NC (n = 399)
Chronic pain without
NC (n = 1611)
P value Severe chronic pain
with NC (n = 218)a
Severe chronic pain
without NC (n = 487)a
P value
SF-12, mean (SD)
Physical function 53.0 (8.0) 37.9 (13.0) 46.1 (11.6) <0.001b 34.4 (12.1) 41.0 (13.0) <0.001
Role physical 53.7 (7.2) 38.3 (12.3) 46.0 (11.2) <0.001 34.5 (11.4) 40.2 (12.4) <0.001
Bodily pain 54.3 (7.0) 33.3 (12.2) 43.0 (11.3) <0.001 29.0 (10.7) 35.9 (12.1) <0.001
General health 52.1 (8.8) 36.7 (13.4) 44.3 (11.7) <0.001 33.6 (13.2) 39.5 (12.4) <0.001
Social function 52.2 (8.5) 38.5 (13.5) 47.0 (11.6) <0.001 34.9 (13.1) 41.8 (13.1) <0.001
Role emotional 51.6 (8.6) 39.4 (14.8) 47.2 (11.9) <0.001 35.8 (15.3) 42.0 (14.4) <0.001
Vitality 53.7 (8.8) 43.5 (11.2) 47.8 (10.2) <0.001 41.9 (11.1) 44.0 (10.9) <0.001
Mental health 51.9 (8.9) 42.7 (11.7) 48.2 (10.5) <0.001 40.3 (12.0) 44.6 (11.5) <0.001
Physical component score 54.0 (7.0) 35.7 (12.8) 44.5 (11.8) <0.001 32.0 (11.6) 38.6 (12.8) <0.001
Mental component score 51.9 (7.0) 43.7 (12.8) 48.8 (11.2) <0.001 41.1 (13.0) 45.2 (12.7) <0.001
EQ-5D index score, mean (SD) 0.93 (0.13) 0.47 (0.34) 0.70 (0.25) <0.001 0.33 (0.35) 0.55 (0.32) <0.001
EQ-VAS, mean (SD) 85.3 (13.5) 59.7 (24.0) 73.4 (19.3) <0.001 51.8 (24.6) 64.3 (22.4) <0.001
Chronic pain grade, n (%)
Grade I – 63 (16.6) 681 (44.3) <0.001c 3 (1.4) 11 (2.3) <0.001
Grade II – 128 (33.8) 518 (33.7) 63 (30.3) 239 (50.6)
Grade III – 76 (21.1) 189 (12.3) 56 (26.9) 111 (23.5)
Grade IV – 112 (29.6) 148 (9.6) 86 (41.3) 111 (23.5)
Pain duration (mo), n (%)
<6 – 16 (4.0) 107 (6.7) 0.005c 7 (3.3) 28 (5.8) 0.290
6–12 – 40 (10.1) 194 (21.1) 19 (8.8) 49 (10.2)
12–36 – 84 (21.2) 417 (26.1) 40 (18.6) 102 (21.3)
P36 – 256 (64.6) 880 (55.1) 149 (69.3) 301 (62.7)
Pain intensity, n (%)
Mild (1–3) – 29 (7.4) 405 (25.8) <0.001c – –
Moderate (4–6) – 145 (37.0) 677 (43.1) – –
Severe (7–10) – 218 (55.6) 487 (31.0) – –
Pain self-efﬁcacy, mean (SD) – 32.99 (17.3) 44.81 (15.0) <0.001c 26.4 (16.0) 34.7 (16.3) <0.001
a Severe pain = average pain intensity score P7/10.
b Chi-squared test; comparisons between ‘‘Chronic pain with NC’’ vs ‘‘Chronic pain without NC’’ and ‘‘Severe chronic pain with NC’’ vs ‘‘Severe chronic pain without NC.’’
c t-Test comparisons between ‘‘Chronic pain with NC’’ vs ‘‘Chronic pain without NC’’ and ‘‘Severe chronic pain with NC’’ vs ‘‘Severe chronic pain without NC.’’
Table 4
Graded categories of chronic pain with neuropathic characteristics, incorporating features of ‘‘refractoriness’’ [41].
n % of all chronic pain
(n = 2202)
% of S-LANSS positive
(n = 399)
B S-LANSS positive 399 18.1 –
C S-LANSS positive and relevant historya 215 9.8 53.88
D S-LANSS positive and relevant history and NO neuropathic pain medications 117 5.3 29.32
E S-LANSS + relevant history + an adequate trial of one or more neuropathic pain medications 98 4.45 24.56
S-LANSS + relevant history + adequate trial P2 NeuP drugs 52 2.36 13.0
S-LANSS + relevant history + adequate trial of P2 NeuP drugs + pain severity P5b 50 2.27 12.5
S-LANSS + relevant history +P2 adequate trials of NeuP drugs + poor quality of lifec 34 1.5 8.5
F S-LANSS + relevant history +P4 adequate trials of NeuP drugs + (poor quality of life c or pain severity
P5) + duration >6 months
10 0.45 2.0
S-LANSS, Self-administered Leeds Assessment of Neuropathic Signs and Symptoms; NeuP, neuropathic pain.
a Relevant history – reported cause of pain dichotomised in those with S-LANSS score P12 to ‘‘Not neuropathic pain’’ (i.e., muscle problems or arthritis) and ‘‘Possible
neuropathic pain’’ (other possible neuropathic pain causes listed).
b Adequate trial – each of these drugs should have been tried for at least 3 months or until adverse effects prevent continued treatment.
c Poor Quality of Life = within the lowest tertile of scores for SF-12 PCS (Physical Component Score) and MCS (Mental Component Score).
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154 (2013) 690–699pain did not have NC. They were also more likely to be unable to
work due to illness or disability, to have no educational qualiﬁca-
tions, and to be smokers. However, amongst those individuals
who reported Severe Chronic pain (pain intensity P7/10), the dif-
ferences in gender and education were not signiﬁcant (Table 2).
Table 3 shows the impact of chronic pain with and without NC,
and also those reporting severe pain. Signiﬁcantly more of those
with Chronic pain with NC reported Grades III and IV of the CPG,
indicating greater disability due to pain (50.7% vs 21.9%,
P < 0.001), and among those with Severe chronic pain, those with
NC were more likely to be disabled as a result of their pain
(68.2% vs 47.0%, P < 0.001) than those with Chronic pain without
NC. Although Chronic pain with NC was associated with greater
pain duration compared to Chronic pain without NC, the duration
of Severe chronic pain was similar in both groups. Chronic painwith NC was associated with signiﬁcantly lower SF-12 scores in
all domains, and with signiﬁcantly lower utility index scores for
EQ-5D and poorer pain self-efﬁcacy than Chronic pain without NC.
3.2. Characteristics of ‘‘possible’’ and ‘‘refractory’’ neuropathic pain
including relevant history, duration, impact, and treatment of
neuropathic pain
The graded categories of chronic pain with neuropathic charac-
teristics, incorporating the features of ‘‘refractoriness,’’ are shown
in Table 4 and Fig. 1. Of the 399 reporting Chronic pain with NC,
215 (53.9%) also reported a relevant medical history of a possible
medical condition known to feature neuropathic pain (Table 4).
In this group of those with ‘‘Possible neuropathic pain’’ (n = 215),
neuralgia was the most commonly reported cause (n = 69, 32.1%),
Table 5
Clinical and associated features of graded possible refractory neuropathic pain.
A B C D E F
Chronic pain without
NC (n = 1611)
Chronic pain with
NC (n = 399)
Possible NeuPa
(n = 215)
Untreated possible
NeuPb (n = 117)
Treated possible
NeuPc (n = 98)
Refractory possible
NeuPd (n = 10)
Age, mean (SD) 56.3 (15.3) 56 (15.4) 56.6 (14.8) 57.6 (16.3) 55.3 (12.7) 51.7 (11.5)
Proportion of respondents by gender, n (%)
Female (n = 2456) 925 (37.7) 251 (10.2) 136 (5.5) 66 (2.7) 70 (2.9) 8 (0.3)
Male (n = 1846) 686 (37.2) 148 (8.0) 79 (4.3) 51 (2.8) 28 (1.5) 2 (0.1)
SF-12, mean (SD)
PCS 44.5 (11.8) 35.7 (12.8) 33.9 (12.7) 36.8 (12.4) 30.3 (12.2) 18.1 (4.4)
MCS 48.8 (11.2) 43.4 (12.8) 43.8 (11.7) 46.6 (11) 40.5 (11.7) 40.3 (9.5)
EQ-5D index score 0.70 (0.25) 0.47 (0.34) 0.45 (0.3) 0.53 (0.3) 0.35 (0.3) 0.01 (0.06)
PSEQ, mean (SD) 44.8 (15) 33 (17.3) 32.2 (17.1) 37.8 (16.4) 25.3 (15.5) 12.6 (7.9)
Average pain intensity 5.2 (2.4) 6.7 (2.2) 6.7 (2.1) 6.2 (2.1) 7.3 (2) 8.3 (1.4)
Pain-related disability (CPG III & IV) 337 (21.9) 188 (49.6) 109 (53.2) 44 (40.0) 65 (68.4) 10 (100)
NeuP, neuropathic pain; PCS, Physical Component Score; MCS, Mental Component Score; PSEQ, Pain Self-Efﬁcacy Questionnaire; CPG, Chronic Pain Grade.
a Self-administered Leeds Assessment of Neuropathic Signs and Symptoms (S-LANSS) positive and relevant history.
b S-LANSS positive and relevant history and no NeuP medications.
c S-LANSS positive and relevant history and adequate trial of at least one NeuP medication.
d Possible NeuP (S-LANSS positive and relevant history) and adequate trial of 4 or more drugs and poor QoL OR pain severity >5 and pain duration more than 6 months.
Table 6
Comparisons of health-related quality of life, general health, and pain self-efﬁcacy between ‘‘Untreated,’’ ‘‘Treated,’’ and ‘‘Refractory’’ possible neuropathic pain (for pain groups
see Table 1), Mean (SD).
D E Mean difference 95% CI P-value
Untreated possible NeuP2 (n = 117) Treated possible NeuP3 (n = 98)
SF-12 PCS 36.8 (12.4) 30.3 (12.2) 6.5 3.1–9.9 <0.001
SF-12 MCS 46.6 (11.0) 40.5 (11.7) 6.1 3.0–9.3 <0.001
EQ-5D 0.53 (0.3) 0.35 (0.3) 0.1 0.1–0.3 <0.001
PSEQ 37.8 (16.4) 25.3 (15.5) 12.5 8.1–17.0 <0.001
D F
Untreated possible NeuP2 (n = 117) Refractory possible4 (n = 10)
SF-12 PCS 36.8 (12.4) 18.1 (4.4) 18.7 10.9–26.6 <0.001
SF-12 MCS 46.6 (11.0) 40.3 (9.5) 6.2 0.8–13.3 0.084
EQ-5D 0.53 (0.3) 0.01 (0.06) 0.5 0.3–0.7 <0.001
PSEQ 37.8 (16.4) 12.6 (7.9) 25.3 14.4–36.3 <0.001
NeuP, neuropathic pain; CI, conﬁdence interval; PCS, Physical Component Score; MCS, Mental Component Score; PSEQ, Pain Self-Efﬁcacy Questionnaire.
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154 (2013) 690–699 695followed by back problems such as slipped disc, back surgery, or
sciatica (n = 67, 31.1%), a surgical operation (n = 45, 20.9%), an acci-
dent that damaged a nerve (n = 35, 16.3%), diabetes (n = 21, 9.8%),
cancer or cancer treatment/chemotherapy (n = 9, 4.2%), shingles
(n = 5, 2.3%), stroke (n = 5, 2.3%), multiple sclerosis (n = 4, 1.9%),
and amputation of a limb (n = 3, 1.4%); 50 (12.5%) of these respon-
dents indicated more than one cause of possible neuropathic pain.
Of these 215 people with ‘‘Possible neuropathic pain,’’ 117 also
indicated that they had never had an ‘‘adequate trial’’ of neuro-
pathic pain medications (‘‘Untreated possible neuropathic pain’’);
the other 98 had had an adequate trial of one or more of these
drugs (‘‘Treated possible neuropathic pain’’) (Table 4). Of individu-
als who had had an adequate trial of at least 2 neuropathic pain
drugs (n = 52), all but 2 respondents also reported an average pain
intensity of at least 5/10, and 34 (8.5% of S-LANSS positive) also had
‘‘poor’’ HRQoL according to their PCS and MCS scores in the SF-12.
There were 10 true ‘‘Refractory’’ cases (positive S-LANSS, relevant
history, adequate trial of 4 or more neuropathic pain medications,
pain intensity at least 5/10, or poor HRQoL).
Comparisons of selected subgroups of those with ‘‘Possible’’ and
‘‘Possible refractory’’ neuropathic pain representing those who had
and had not been treated with adequate trials of neuropathic pain
medications are shown in Table 5, representing grades of ‘‘refracto-
riness.’’ We were unable to conduct statistical testing between
these groups, as they are not mutually independent (i.e., individu-
als belong to more than one group, see Table 1). Pairwise compar-
isons between ‘‘Untreated possible neuropathic pain,’’ ‘‘Treatedpossible neuropathic pain,’’ and ‘‘Refractory possible neuropathic
pain’’ are shown in Table 6.
The mean age of those in the ‘‘Possible,’’ ‘‘Untreated Possible,’’
and ‘‘Treated Possible’’ neuropathic groups ranged from 55.3 to
57.6 years, with the ‘‘Refractory Possible’’ neuropathic group
slightly younger, with a mean age of 51.7 years (SD 11.5) (Table 5).
The proportions of male and female responders are similar in the
graded groups. In responses to both of the HRQoL questionnaire
instruments, there was a decline in scores with each gradation of
‘‘refractoriness,’’ that is, addition of characteristics from the agreed
expert deﬁnition [42]. These differences were more apparent in re-
sponses to the SF-12 PCS and in the proportion with severe pain-
related disability measured by the CPG. The ‘‘Refractory Possible’’
neuropathic pain group was found to have the poorest physical
and mental health component scores in the SF-12, the lowest EQ-
5D index scores, lowest pain self-efﬁcacy, and the highest pain
severity.
Comparing those who had been treated (i.e., prescribed an ade-
quate trial of at least one neuropathic pain drug) with those who
reported no neuropathic pain treatment, we found signiﬁcant dif-
ferences in SF-12 PCS and MCS scores, EQ-5D, and PSEQ scores,
with those with ‘‘Untreated possible neuropathic pain’’ reporting
higher HRQoL and self-efﬁcacy scores, indicating better overall
health (Table 6). The much poorer scores in all these measures
among those with ‘‘Refractory possible’’ neuropathic pain were
found to be signiﬁcant (with the exception of the SF-12 MCS) de-
spite the small numbers in this group.
Fig. 1. Outline of respondents chronic pain status/groups for analysis. S-LANSS, Self-administered Leeds Assessment of Neuropathic Signs and Symptoms; NeuP, NeuP,
neuropathic pain; NC, neuropathic characteristics; HRQoL, health-related quality of life.
Table 7
Consultations with the GP for pain, n (%).a
Chronic pain without NC (n = 1569) Possible neuropathicb (n = 215) Treated possiblec (n = 98) Refractory possible neuropathicd (n = 10)
Consultations about pain condition with their GP in past 6 months
None 790 (50.4) 51 (25.1) 19 (20.2) 2 (20)
1–3 623 (39.7) 95 (46.8) 38 (40.4) 3 (30)
4–6 101 (6.3) 34 (16.7) 19 (20.2) 2 (20)
More than 6 55 (3.4) 23 (11.3) 18 (19.1) 3 (30)
GP, general practitioner; NC, neuropathic characteristics.
a Values are valid n (%).
b Self-administered Leeds Assessment of Neuropathic Signs and Symptoms (S-LANSS) positive and relevant history and no neuropathic pain (NeuP) medications.
c S-LANSS positive and relevant history and adequate trial of at least one NeuP medication.
d Possible NeuP (S-LANSS positive and relevant history) and adequate trial of 4 or more drugs and poor QoL OR pain severity >5 and pain duration more than 6 months.
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The highest proportion of people with chronic pain who had not
visited their GP in the previous 6 months regarding the illness or
medical condition that caused their pain were those with Chronic
pain without NC (50%; n = 790) (Table 7). Almost 80% (n = 75) of
those with ‘‘Treated possible’’ neuropathic pain had attended morethan once. Half of those with ‘‘Refractory possible’’ neuropathic
pain (n = 5) had attended their GP more than 4 times in the previ-
ous 6 months.
Referral to a pain specialist was most common in the ‘‘Refrac-
tory possible’’ neuropathic pain group (70%, n = 7) compared to
6.7% (n = 106) of those reporting Chronic pain without NC. Among
those with Severe chronic pain (P7/10), individuals who reported
pain with NCs were signiﬁcantly more likely to have attended a
Fig. 2. Proportion of pain respondents who are currently or have ever consulted a health care professional for their chronic pain (n = 1569 individuals without neuropathic
characteristics [NC]; n = 215 Possible Neuropathica; n = 98 Treated Possibleb; n = 10 Refractory Possible neuropathicc). aS-LANSS (Self-administered Leeds Assessment of
Neuropathic Signs and Symptoms) positive and relevant history and no neuropathic pain (NeuP) medications. bS-LANSS positive and relevant history and adequate trial of at
least one NeuP medication. cPossible NeuP (S-LANSS positive and relevant history) and adequate trial of 4 or more drugs and poor QoL OR pain severity >5 and pain duration
more than 6 months.
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reporting Severe Chronic pain without NC (21.8% [n = 46] vs
10.5% [n = 50], P < 0.001). Of health care professionals consulted
for pain, the GP was the most commonly reported by all groups,
followed by a physiotherapist (Fig. 2).
4. Discussion
This study uniquely incorporates the essential features of an
international consensus on measuring the epidemiology of refrac-
tory neuropathic pain [42] in a questionnaire survey of a large gen-
eral population sample. ‘‘Possible’’ neuropathic pain is relatively
common, accounting for about 10% (215/2202) of people with
chronic pain and 53.9% of those reporting neuropathic characteris-
tics on the S-LANSS. It is associated with poorer physical, psycho-
logical, and social health than Chronic pain without NC, though
all chronic pain is associated with poor health [38]. Although truly
‘‘refractory’’ neuropathic pain, as deﬁned by international experts,
is relatively uncommon (affecting just 5% of those with possible
neuropathic pain), it is associated with severe pain and pain-re-
lated disability and extremely poor health in all dimensions; this
is despite numerous attempts at pharmacological treatment and
high use of health services. While a relatively low response rate
prevents accurate estimates of prevalence, it is apparent that there
is a signiﬁcant proportion of people in the community with persis-
tent neuropathic-type pain that remains untreated or undertreat-
ed, with no adequate trials of effective medication. Until this
proportion of patients has been exposed to adequate treatment
(deﬁned within the Introduction), we are unable to estimate the
proportion of patients with truly refractory neuropathic pain.
This study comprises a large dataset derived from a random
sample of adults generated from GP practices located across the
UK. The questionnaire contained well-validated questionnaire
instruments, including the S-LANSS, which enabled us to catego-
rise respondents as having chronic pain with and without neuro-
pathic characteristics [4]. The relatively low response rate is
similar to those in previous surveys of pain prevalence [7,27],
and an increasingly common problem in epidemiological research
[17,25,27]. The questionnaire was sent to a number of areas of high
deprivation (particularly in Glasgow), and low socioeconomic sta-tus is known to be associated with poorer response rates [17,50].
The main concern with low response is that it introduces the po-
tential for responder bias, making it difﬁcult to generalise preva-
lence estimates to the population. In this paper we therefore
focused on the proportion of all chronic pain represented by possi-
ble (refractory) neuropathic pain, and on comparisons between
well-deﬁned pain subgroups. Despite the response rate, we found
that the proportion of the sample reporting any chronic pain was
very similar to that found in a previous study using an identical
case deﬁnition and with a response rate of 81% [14]. We also found
that chronic pain with NC was reported by a similar proportion
(8.9%) and similar sociodemographic associations as in previous re-
search with higher response rates [6,46].
We are likely to have overestimated ‘‘Possible neuropathic
pain,’’ as some of the diagnoses included in the list might include
nonneuropathic pain (e.g., back pain). However, these reported
chronic pains may have a neuropathic contribution, and can be
considered as a spectrum, ‘‘more or less neuropathic’’ [3]. It is
likely, given the positive S-LANSS, that those individuals in this
group had an important neuropathic contribution to their pain;
without clinical examination it is impossible to comprehensively
identify ‘‘possible,’’ ‘‘probable,’’ or ’’deﬁnite’’ neuropathic pain,
and a population-based questionnaire survey can only approxi-
mate [48]. Although we relied on self-report for the categorisation
of respondents, the instruments we used were all well validated
[4,14,15,52,53]. The questions on the self-reported diagnoses of
causes of pain, and the drug history were not formally validated.
We made these as user-friendly as possible, with a comprehensive
checklist, and tested them in a pilot study. Previous research based
on electronic prescribing records has described in detail the
changes in prescribing for neuropathic pain [19]. With our current
data, we cannot conﬁrm the validity of responses to pain diagnoses
or drug history, and further research, based on reviewing medical
records, is necessary to examine this.
We have been conservative in our approach to identifying those
individuals who had an ‘‘adequate trial’’ of a neuropathic pain
medication. It was apparent that, on some occasions, these drugs
were not prescribed for chronic possible neuropathic pain, for
example, opioids, tramadol, and morphine, where respondents
indicated that they had taken these drugs for an acute episode of
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from criteria for an adequate trial. Conversely, a number of individ-
uals indicated that they had taken neuropathic pain medication ‘‘in
the past,’’ but did not specify the length of time these were pre-
scribed/taken for; again, we excluded these people from the ‘‘ade-
quate trial’’ criteria. It is possible this may have resulted in
misclassiﬁcation. We did not ask about dosage of the neuropathic
pain medications, as this was felt to be too onerous for respon-
dents, possibly further diminishing the response rate, and unlikely
to be accurately reported. Future research, with more detailed drug
history, is required to explore this. Levels of prescribing in studies
in general practice settings is generally low in patients with pre-
sumed neuropathic pain [2,18,47] (identiﬁed by screening ques-
tionnaires, such as the S-LANSS and DN4) and in patients with
speciﬁc neuropathic pain diagnoses, such as postherpetic neuralgia
(PHN) [12]. In our study, three quarters of respondents with ‘‘Pos-
sible neuropathic pain’’ (S-LANSS positive and relevant history)
had consulted their GP regarding their pain in the previous
6 months, suggesting that opportunities to improve management
and treatment may have been missed. This is likely to be for a com-
bination of reasons, including education and resources. Recent
guidelines describe the full range of drug treatments available
[1,16] and, in the UK, evidence-based guidelines focus on primary
care/nonspecialist settings [31]. This work highlights the scale of
under- or untreated neuropathic pain, and the opportunity to im-
prove its management in primary care, where the great majority
of these pain patients exist.
Previous research has found the presence of neuropathic pain to
be associated with poor health in every dimension: physical, psy-
chological, and social [11,41]. In this study, among individuals
reporting Chronic pain with NC, we found similar physical and
mental component summary scores (PCS/MCS) for the SF-12 ques-
tionnaire to those in a French nationwide general population sur-
vey [2]. Our EQ-5D utilities were generally lower (indicating
poorer quality of life) than those in some other chronic conditions,
including cancer, heart failure, chronic obstructive pulmonary dis-
ease, type 2 diabetes, Parkinson disease, and stroke [11], although
they are comparable to other studies of neuropathic pain condi-
tions: Chronic pain with NC (mean EQ-5D utility index 0.47) was
comparable to a Canadian study of patients with peripheral neu-
ropathy determined by the Toronto Clinical Neuropathy Score
[36], and also to mean pooled utility scores for diabetic neuropathy
(0.61), PHN (0.61), and mixed neuropathic pain (0.43) [11]. Fur-
thermore, in our study, the ‘‘Refractory possible’’ neuropathic pain
group had the lowest mean EQ-5D health utility index score (mean
0.01), even lower than those found in studies of failed back surgery
syndrome (0.15) and central neuropathic pain (0.23) [11]. An EQ-
5D index score of 0 is ‘‘equal to death’’ [22], highlighting the ex-
treme detrimental and debilitating burden that refractory neuro-
pathic pain exerts on these individuals, encompassing all aspects
of HRQoL. This is conﬁrmed by the very low self-efﬁcacy scores,
indicating that patients in this group do not feel conﬁdent to per-
form their normal activities in the presence of this pain. Other re-
search has found the health impact of any neuropathic pain
appears to be worse than that of nonneuropathic pain of equivalent
intensity [40,41], and the burden is more dependent on its inten-
sity than the cause [11]. Attal et al. (2011) suggest that it is the par-
ticular features, the strange and unpleasant signs and symptoms of
this type of pain, and the distressing and unpleasant nature of the
symptoms themselves that impact on quality of life [2].
In this cross-sectional study, it is impossible to determine the
temporal nature of associations, particularly those linking refrac-
tory pain with quality of life and pain self-efﬁcacy. Our ﬁndings
indicate that it is possible that medical treatment makes these
worse; however, the greater intensity and disability scores suggest
that people with worse neuropathic pain are more likely to seekand receive adequate treatment (Tables 5 and 6), and that this will
explain the link. Further research is required. We did not include
questions about the use of drugs that were not speciﬁc to neuro-
pathic pain in the list used to determine refractoriness. While this
is consistent with current evidence [1,16] and the Delphi survey
[42], it may have excluded those with mild neuropathic pain, per-
haps controlled by paracetamol (acetaminophen) or other simple
analgesics. These individuals are likely to have been included in
the ‘‘Untreated Possible neuropathic pain’’ group. Note, though,
that those with untreated neuropathic pain still had relatively poor
HRQoL and severe pain, and many are likely to beneﬁt from further
assessment with a view to effective treatment.
Health care resources were widely used by all those with
chronic pain. Overall, the GP was most commonly the health pro-
fessional who was currently consulted about pain by all respon-
dents, and similar results were reported across Europe by Breivik
et al. [7]. There was greater use of health services in both primary
care and specialist health care in the most refractory groups, where
70% had attended a pain management specialist, and had been pre-
scribed a number of neuropathic pain medications (n = at least 4
drugs in the ‘‘Refractory possible’’ neuropathic pain group). We
have identiﬁed a number of patients who report highly disabling
pain and for whom adequate pain management does not appear
to have been achieved. There is limited research on the effective-
ness of standard psychological or multidisciplinary treatment pro-
grammes speciﬁcally designed for patients with chronic
neuropathic pain, although it has been suggested that it is reason-
able to extrapolate from successful trials in other types of chronic
pain [10,49].
4.1. Conclusions
This study has found that truly refractory neuropathic pain (as
deﬁned by an international group of experts) is relatively uncom-
mon. However, we have shown that there are many more individ-
uals whose neuropathic pain has been unsuccessfully treated, and
who have increasingly severe pain-related disability, poor quality
of life, and high health care use. Most importantly, there is a signif-
icant proportion of chronic pain in the community that is appar-
ently persistent and neuropathic, but that appears undertreated
or untreated.
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